Key result
Double or triple antithrombotic combination therapy strategies in patients with atrial fibrillation are reviewed in light of recent consensus documents, as powered randomized trials are lacking.
Why the study?
What is the optimal strategy to balance bleeding and ischaemic events in patients with atrial fibrillation requiring antiplatelet therapy on top of anticoagulation?
What is the optimal strategy to balance bleeding and ischaemic events in patients with atrial fibrillation requiring antiplatelet therapy on top of anticoagulation?
This review summarizes current developments and consensus guidelines on managing patients with atrial fibrillation who require both anticoagulation and antiplatelet therapy.
Relies on consensus amid absent powered RCTs for antithrombotic therapy in AF; leaves open optimal bleeding-ischaemic balance pending dedicated trials.
The optimal strategy to balance bleeding and ischaemic events in patients with atrial fibrillation, requiring antiplatelet therapy on top of anticoagulation, is subject to debate, since specifically designed and powered randomized trials are not available yet. The review aims to highlight the current developments in the light of the 2014 joint consensus document of the European Society of Cardiology (ESC) Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS) and of the 2014 ESC myocardial revascularization guidelines, both published recently.
No takes yet. Share an insight, caveat, or question.
Rohla et al. (2015) conducted a review in Atrial fibrillation requiring antiplatelet therapy and anticoagulation. Double or triple antithrombotic combination therapy was evaluated. Double or triple antithrombotic combination therapy strategies in patients with atrial fibrillation are reviewed in light of recent consensus documents, as powered randomized trials are lacking.